Press release
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
Developed in Partnership with Healthcare Professionals and Patients, Let’s Talk About LGSOC Provides Information Related to the Biology, Diagnosis,
About this update from Verastem, Inc.
[{"type":"text","content":"\nDeveloped in Partnership with Healthcare Professionals and Patients, Let’s Talk About LGSOC Provides Information Related to the Biology, Diagnosis, Treatment, and Patient Experience\n\n\n BOSTON--(BUSINESS WIRE)--\nVerastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the launch of the new healthcare professional component of Let’s Talk About LGSOC, designed to support clinicians in the diagnosis and management of low-grade serous ovarian cancer (LGSOC). Let’s Talk About LGSOC provides detailed information about the unique clinical, histopathological, and molecular features of LGSOC, current National Comprehensive Cancer Network® (NCCN®) clinical practice guidelines and additional medical and scientific information and resources.\n\n\nLGSOC of the ovary, fallopian tubes, and peritoneum is a rare tumor that commonly affects younger women, with a median age of diagnosis between 45-55 years. For many patients, LGSOC symptoms and treatment side effects have a long-lasting impact on physical and mental health. To date, limited treatment options are available for LGSOC and no treatments have yet been approved by regulatory authorities specifically for the treatment of LGSOC with doctors and patients often resorting to using treatments that may have originally been developed for other tumors.\n\n\n“LGSOC has only recently been classified as a separate disease as compared to the more common high-grade serous ovarian cancer (HGSOC) with different epidemiology, pathology, clinical presentation, and outcomes. Furthermore, the fact that it is rare and disproportionally affects younger women than its high-grade counterpart means we need to ensure the healthcare community is aware that this form of ovarian cancer can impact women at any age and the management approach is not the same as for other ovarian cancers,” said Premal Thaker, MD, David and Lynn Mutch Distinguished Professor of Obstetrics & Gynecology at Washington University School of Medicine. “Let’s Talk About LGSOC has already become a valuable information hub for patients and I believe this LGSOC specific website will be a tremendous resource for healthcare professionals as we seek to provide better care for our patients.”\n\n\nLGSOC represents approximately 10% of all ovarian cancers with an...